Boston continues its growth as the nation’s top biopharma cluster with the announcement by GenesisM that it had broken ground on its 154,000-sq-ft Class A biomanufacturing facility in nearby Bedford, MA. GenesisM is a joint venture between Bain Capital Real Estate and Botanic Properties.
The project marks a significant step forward in addressing the critical need for purpose-built life sciences manufacturing infrastructure in the Greater Boston region, according to Joshua Zinns, managing principal of Botanic Properties, adding that GenesisM’s proprietary enhanced core design provides a strong initial build-out that reduces tenant fit-out time and capital costs.
The facility, which is designed to support multiple tenants operating independently within regulated manufacturing suites, will feature 27-foot ceiling heights, up to 18 loading berths, 12,000 amps of power, and 40′ x 40′ column spacing. GenesisM’s enhanced core platform is designed to provide long-term operational flexibility, accelerate buildout timelines, and reduce upfront capital requirements for tenants, continued Zinns.
Construction is currently underway, with tenant fit-out commencing as early as Q2 2026 and final core and shell delivery expected in Q3 2026.
